Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Performance

LPCN opened at $5.01 on Friday. The stock’s 50 day moving average price is $5.10 and its 200-day moving average price is $5.65. Lipocine has a one year low of $2.38 and a one year high of $11.79. The stock has a market cap of $26.80 million, a price-to-earnings ratio of -6.78 and a beta of 1.18.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, analysts predict that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC grew its position in Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the period. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 at the end of the most recent quarter. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.